Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mTOR pathway in triple-negative breast cancer cells-Reference-Cited by-同舟云学术

Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mTOR pathway in triple-negative breast cancer cells

Published:2024-01-13 Issue:2 Volume:41 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Sharma Preeti^ORCID,Chaturvedi Shubhra,Khan Mohammad Ahmed,Rai Yogesh,Bhatt Anant Narayan,Najmi Abul Kalam,Akhtar Mohd.^ORCID,Mishra Anil Kumar

Funder

ICMR

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12032-023-02274-5.pdf

Reference64 articles.

1. Khan MA, Jain VK, Rizwanullah M, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019;24(11):2181–91. https://doi.org/10.1016/j.drudis.2019.09.001.

2. Pawar A, Prabhu P. Nanosoldiers: a promising strategy to combat triple negative breast cancer. Biomed Pharmacother. 2019;110:319–41. https://doi.org/10.1016/j.biopha.2018.11.122.

3. Beniey M, Hubert A, Haque T, Cotte AK, Béchir N, Zhang X, Tran-Thanh D, Hassan S. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. Br J Cancer. 2023;20:1–2. https://doi.org/10.1038/s41416-023-02226-w.

4. Yue X, Li M, Chen D, Xu Z, Sun S. UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. Exp Ther Med. 2018;16(5):3921–8. https://doi.org/10.3892/etm.2018.6675.

5. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:1–3. https://doi.org/10.1186/s13058-020-01296-5.